Similar articles for PMID: 31205558

Year	Number of Results
2010	6
2011	5
2012	6
2013	4
2014	6
2015	7
2016	11
2017	13
2018	21
2019	25
2020	3
2021	3
2022	3
2023	4
2024	0

1

The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases.

Wang C, Lu X, Zhou Z, Wang J, Hui Z, Liang J, Feng Q, Chen D, Xiao Z, Lv J, Wang X, Wang X, Zhang T, Deng L, Wang W, Xiao J, Li J, Bi N, Wang L. Wang C, et al. J Cancer. 2019 May 12;10(9):1985-1990. doi: 10.7150/jca.30131. eCollection 2019. J Cancer. 2019. PMID: 31205558 Free PMC article.

2

Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.

Magnuson WJ, Yeung JT, Guillod PD, Gettinger SN, Yu JB, Chiang VL. Magnuson WJ, et al. Int J Radiat Oncol Biol Phys. 2016 Jun 1;95(2):673-9. doi: 10.1016/j.ijrobp.2016.01.037. Epub 2016 Feb 2. Int J Radiat Oncol Biol Phys. 2016. PMID: 27034176

3

Outcomes according to initial and subsequent therapies following intracranial progression in patients with EGFR-mutant lung cancer and brain metastasis.

Hyun DG, Choi CM, Lee DH, Kim SW, Yoon S, Kim WS, Ji W, Lee JC. Hyun DG, et al. PLoS One. 2020 Apr 16;15(4):e0231546. doi: 10.1371/journal.pone.0231546. eCollection 2020. PLoS One. 2020. PMID: 32298306 Free PMC article.

4

The Sequence of Intracranial Radiotherapy and Systemic Treatment With Tyrosine Kinase Inhibitors for Gene-Driven Non-Small Cell Lung Cancer Brain Metastases in the Targeted Treatment Era: A 10-Year Single-Center Experience.

Yang S, Xiao J, Liu Q, Zhang Y, Bi N, Huang X, Chen X, Wang K, Ma Y, Deng L, Wang W, Zhao R, Li J, Yi J, Wang S, Li Y. Yang S, et al. Front Oncol. 2021 Oct 14;11:732883. doi: 10.3389/fonc.2021.732883. eCollection 2021. Front Oncol. 2021. PMID: 34722275 Free PMC article.

5

Upfront Cranial Radiotherapy vs. EGFR Tyrosine Kinase Inhibitors Alone for the Treatment of Brain Metastases From Non-small-cell Lung Cancer: A Meta-Analysis of 1465 Patients.

Du XJ, Pan SM, Lai SZ, Xu XN, Deng ML, Wang XH, Yao DC, Wu SX. Du XJ, et al. Front Oncol. 2018 Dec 12;8:603. doi: 10.3389/fonc.2018.00603. eCollection 2018. Front Oncol. 2018. PMID: 30619745 Free PMC article.

6

Concurrent brain radiotherapy and EGFR-TKI may improve intracranial metastases control in non-small cell lung cancer and have survival benefit in patients with low DS-GPA score.

Liu Y, Deng L, Zhou X, Gong Y, Xu Y, Zhou L, Wan J, Zou B, Wang Y, Zhu J, Ding Z, Peng F, Huang M, Ren L, Lautenschlaeger T, Kong FS, Lu Y. Liu Y, et al. Oncotarget. 2017 Nov 30;8(67):111309-111317. doi: 10.18632/oncotarget.22785. eCollection 2017 Dec 19. Oncotarget. 2017. PMID: 29340055 Free PMC article.

7

Efficacy of brain radiotherapy plus EGFR-TKI for EGFR-mutated non-small cell lung cancer patients who develop brain metastasis.

Wang W, Song Z, Zhang Y. Wang W, et al. Arch Med Sci. 2018 Oct;14(6):1298-1307. doi: 10.5114/aoms.2018.78939. Epub 2018 Oct 23. Arch Med Sci. 2018. PMID: 30393484 Free PMC article.

8

Optimal Sequence of Local and EGFR-TKI Therapy for EGFR-Mutant Non-Small Cell Lung Cancer With Brain Metastases Stratified by Number of Brain Metastases.

Miyawaki E, Kenmotsu H, Mori K, Harada H, Mitsuya K, Mamesaya N, Kawamura T, Kobayashi H, Nakashima K, Omori S, Wakuda K, Ono A, Naito T, Murakami H, Endo M, Nakasu Y, Gon Y, Takahashi T. Miyawaki E, et al. Int J Radiat Oncol Biol Phys. 2019 Jul 1;104(3):604-613. doi: 10.1016/j.ijrobp.2019.02.051. Epub 2019 Mar 6. Int J Radiat Oncol Biol Phys. 2019. PMID: 30851347

9

Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study.

He ZY, Li MF, Lin JH, Lin D, Lin RJ. He ZY, et al. Cancer Manag Res. 2019 Mar 14;11:2129-2138. doi: 10.2147/CMAR.S184922. eCollection 2019. Cancer Manag Res. 2019. PMID: 30936745 Free PMC article.

10

Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis.

Chen Y, Wei J, Cai J, Liu A. Chen Y, et al. BMC Cancer. 2019 Aug 9;19(1):793. doi: 10.1186/s12885-019-6005-6. BMC Cancer. 2019. PMID: 31399067 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

106 results

Results by year